Efficacy of DPP-4 Inhibitors, GLP-1 Analogues, and SGLT2 Inhibitors As Add-ons to Metformin Monotherapy in T2DM Patients: a Model-based Meta-analysis

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2018 Nov 6

PMID 30394576

Citations 13

Authors

Hiroyuki Inoue

Yoko Tamaki

Yushi Kashihara

Shota Muraki

Makoto Kakara

Takeshi Hirota

Ichiro Ieiri

Affiliations

Soon will be listed here.

Abstract

Aims: The aim of the present study was to quantitate the hypoglycaemic effects of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1r) and sodium glucose cotransporter 2 inhibitors (SGLT2i) as add-on treatments to metformin monotherapy in patients with type 2 diabetes mellitus (T2DM) using a model-based meta-analysis (MBMA).

Methods: A systematic literature search of public databases was conducted to develop models that describe the time courses of the fasting plasma glucose (FPG)- and haemoglobin A1c (HbA1c)-lowering effects of three antidiabetic classes using NONMEM 7.3.0.

Results: Seventy-six publications were eligible for this study, and 873 FPG and 1086 HbA1c values were collected. We developed a physiological indirect response model that described the time courses of FPG and HbA1c and simulated reductions in these values 90 days after the initiation of add-on treatments. FPG and HbA1c reductions with once weekly exenatide, liraglutide and dulaglutide were greater than those with other drugs. Mean changes from baseline FPG and HbA1c with these drugs were as follows: exenatide (-22.5 and -16.6%), liraglutide (-22.1 and -16.3%), and dulaglutide (-19.3 and -14.3%). The hypoglycaemic effects of DPP-4i and SGLT2i were similar.

Conclusions: Once weekly exenatide, liraglutide and dulaglutide provided better hypoglycaemic effects among the antidiabetic drugs analysed. Long-acting GLP-1r appears to be more useful for T2DM patients inadequately controlled with metformin monotherapy.

Citing Articles

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion.

Sato H, Ishikawa A, Yoshioka H, Jin R, Sano Y, Hisaka A Sci Rep. 2024; 14(1):24695.

PMID: 39433865 PMC: 11493964. DOI: 10.1038/s41598-024-76256-6.

GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review.

Furio-Novejarque C, Diez J, Bondia J J Diabetes Sci Technol. 2024; 19(2):332-339.

PMID: 39411979 PMC: 11571630. DOI: 10.1177/19322968241285925.

Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches.

Heidarpour M, Mojarad M, Mazaheri-Tehrani S, Kachuei A, Najimi A, Shafie D Int J Endocrinol. 2024; 2024:9900213.

PMID: 38500709 PMC: 10948218. DOI: 10.1155/2024/9900213.

The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions.

Agress S, Sheikh J, Ramos A, Kashyap D, Razmjouei S, Kumar J Curr Cardiol Rev. 2024; 20(3):13-29.

PMID: 38347774 PMC: 11284697. DOI: 10.2174/011573403X289572240206112303.

Metformin ameliorates insulin resistance, thyroid nodules and thyroid function.

Ji S, Gao R, Gao Q, Leng L, Gai N Am J Transl Res. 2023; 15(10):6180-6188.

PMID: 37969194 PMC: 10641348.

References

Eurich D, Simpson S, Majumdar S, Johnson J . Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy. 2005; 25(6):810-6. DOI: 10.1592/phco.2005.25.6.810. View

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View

Ahn J, French J . Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn. 2010; 37(2):179-201. DOI: 10.1007/s10928-010-9152-6. View

Zintzaras E, Miligkos M, Ziakas P, Balk E, Mademtzoglou D, Doxani C . Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. Clin Ther. 2014; 36(10):1443-53.e9. DOI: 10.1016/j.clinthera.2014.06.035. View

Lund A, Knop F, Vilsboll T . Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014; 25(5):407-14. DOI: 10.1016/j.ejim.2014.03.005. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014; 38(1):140-9. DOI: 10.2337/dc14-2441. View

Kayaniyil S, Lozano-Ortega G, Bennett H, Johnsson K, Shaunik A, Grandy S . A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. Diabetes Ther. 2016; 7(1):27-43. PMC: 4801811. DOI: 10.1007/s13300-016-0155-1. View

Alexander S, Christopoulos A, Davenport A, Kelly E, Marrion N, Peters J . THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol. 2017; 174 Suppl 1:S17-S129. PMC: 5650667. DOI: 10.1111/bph.13878. View

Stringer F, DeJongh J, Enya K, Koumura E, Danhof M, Kaku K . Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes. Diabetes Technol Ther. 2014; 17(3):215-23. PMC: 4346657. DOI: 10.1089/dia.2014.0222. View

10.

. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7):1327-34. PMC: 2699715. DOI: 10.2337/dc09-9033. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

12.

Glaesner W, Vick A, Millican R, Ellis B, Tschang S, Tian Y . Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010; 26(4):287-96. DOI: 10.1002/dmrr.1080. View

13.

Shichiri M, Kishikawa H, Ohkubo Y, Wake N . Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23 Suppl 2:B21-9. View

14.

Lledo-Garcia R, Mazer N, Karlsson M . A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn. 2013; 40(2):129-42. DOI: 10.1007/s10928-012-9289-6. View

15.

Frias J, Guja C, Hardy E, Ahmed A, Dong F, Ohman P . Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised.... Lancet Diabetes Endocrinol. 2016; 4(12):1004-1016. DOI: 10.1016/S2213-8587(16)30267-4. View

16.

Boccuzzi S, Wogen J, Fox J, Sung J, Shah A, Kim J . Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001; 24(8):1411-5. DOI: 10.2337/diacare.24.8.1411. View

17.

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49(11):2564-71. DOI: 10.1007/s00125-006-0416-z. View

18.

Brown J, Conner C, Nichols G . Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2009; 33(3):501-6. PMC: 2827496. DOI: 10.2337/dc09-1749. View

19.

Harding S, Sharman J, Faccenda E, Southan C, Pawson A, Ireland S . The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2017; 46(D1):D1091-D1106. PMC: 5753190. DOI: 10.1093/nar/gkx1121. View

20.

DeYoung M, MacConell L, Sarin V, Trautmann M, Herbert P . Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011; 13(11):1145-54. PMC: 3202891. DOI: 10.1089/dia.2011.0050. View